

# Multiple Myeloma and Lymphoma Research Symposium

**Wednesday, April 26, 2023**

**9 AM – 5 PM**

Center for Discovery and Innovation  
111 Ideation Way, Nutley, NJ 07110

## Overview

Recent advances in bench-to-bedside research have led to expanding treatment options and significantly improved outcomes in B-cell malignancies, including multiple myeloma and B-cell lymphomas. This Symposium will feature timely presentations from leading researchers at the forefront of this field, with the goal of stimulating additional basic science and clinical breakthroughs, to the benefit of patients with these diseases.

**This is a complimentary program.**

## Target Audience

This symposium is designed for scientists, physicians, fellows, residents, students and health care professionals involved in research activities or in clinical settings.



Scan QR Code to [Register](#)

Or go to [link](#).

## Organizers

**Institute for Multiple Myeloma and Lymphoma**  
at the



## Sponsors



The symposium is receiving funding from the **Torque Foundation** through a gift to Georgetown Lombardi Comprehensive Cancer Center

**8:15 AM 9:15 AM Arrival and Breakfast - CDI Lobby**

**9:00 AM 9:15 AM Slide Presentation Check**

**9:15 AM 9:30 AM Overview**  
**David Perlin, PhD and Benjamin Tycko, MD PhD**

**9:30 AM 10:15 AM Introduced by Andre Goy, MD**  
**Laura Pasqualucci, MD**  
Professor, Institute for Cancer Genetics, Columbia University  
***Genetics-driven enhanceosome dysregulation in B-cell lymphomas***

**10:15 AM 11:00 AM Introduced by Louis Weiner, MD**  
**Kieron M Dunleavy, MD**  
Professor and Director, Hematological Malignancies  
Lombardi Comprehensive Cancer Center and Medstar Health,  
Georgetown University  
***Novel insights and approaches in aggressive B-cell lymphomas***

**11:00 AM 11:45 AM Introduced by Rena Feinman, PhD**  
**Jing Yang, PhD**  
Associate Professor of Oncology, Houston Methodist Cancer  
Center  
***Tumor microenvironment and therapeutic resistance in multiple myeloma***

**11:45 AM 12:45 PM LUNCH BREAK – CDI Lobby**

**12:45 PM 1:45 PM Keynote lecture**  
Introduced by **David Siegel, MD PhD**  
**Irene Ghobrial, MD**  
Professor, Dana-Farber Cancer Institute, Harvard Medical  
School  
***The PROMISE of early detection in multiple myeloma***

**1:45 PM 2:30 PM Introduced by Benjamin Tycko, MD PhD**  
**Samir Parekh, MD**  
Professor, Tisch Cancer Institute, Mount Sinai  
***Promise and challenges with immunotherapy in myeloma***

**2:30 PM 3:15 PM Introduced by Rena Feinman, PhD**  
**David Fooksman, PhD**  
Associate Professor, Albert Einstein College of Medicine  
***Mechanisms regulating myeloma cell dynamics in the bone marrow***

**3:15 PM 3:30 PM Closing Remarks**  
**Rena Feinman, PhD and Benjamin Tycko, MD PhD**

**3:30 PM 5:00 PM CDI Lobby : Informal Wine Reception**

# Multiple Myeloma and Lymphoma Research Symposium

## SPEAKER BIOGRAPHIES

KEYNOTE SPEAKER

### Irene Ghobrial, MD

Professor of Medicine

Dana-Farber Cancer Institute, Harvard Medical School



Dr. Ghobrial completed her M.D. at Cairo University and a residency in Internal Medicine at Wayne State University in Detroit, Michigan, then trained as a Hematology/Oncology Fellow at the Mayo Clinic in Rochester, Minnesota. She is currently a Professor of Medicine and the Lavine Family Chair for Preventative Cancer Therapies at Dana-Farber Cancer Institute, Harvard Medical School. She is the Director of Translational Research in the Department of Multiple Myeloma, Director of the Center for Prevention of Progression diseases (CPOP), and co-leader of the Lymphoma and Myeloma Program at Dana-Farber. She is the co-leader of the Stand Up to Cancer Myeloma Dream Team—the first Dream Team award for blood cancer, the recipient of the Claire W. and Richard P. Morse Research Award, the Jan Gosta Waldenstrom Award, and the William Dameshek Prize given annually by The American Society of Hematology (ASH) to an individual younger than 50 who has made outstanding contributions in hematology.

Her research focuses on identifying and developing effective therapeutic interventions for precursor conditions of myeloma (Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma, MGUS and SMM). The focus of her research is to identify novel biomarkers of disease progression and develop potentially curative therapies in the pre-malignant phase that exploit the immune microenvironment in the bone marrow. She developed a large, patient-empowering observational study for these precursor conditions, the PCROWD study. She is also the PI of the first screening study for multiple myeloma in the US, the PROMISE study, which is currently screening 30,000 high-risk individuals, including those of African descent or with a family history of blood cancer.

INVITED SPEAKER

### Laura Pasqualucci, MD

Professor of Pathology and Cell Biology

Institute for Cancer Genetics, Columbia University



Laura Pasqualucci, MD, is a Professor of Pathology and Cell Biology in the Institute for Cancer Genetics, Columbia University. She received her medical degree from the University of Perugia Medical School, where she completed her residency in hematology. She then moved to the United States for a post-doctoral fellowship in the molecular genetics of lymphoma with Dr. Riccardo Dalla-Favera at Columbia University, where she was promoted to a faculty position in 2001.

Over the last 25 years, Dr. Pasqualucci's research has focused on the identification and functional characterization of genetic lesions implicated in the pathogenesis of B cell lymphomas, including their in vivo modeling, with the ultimate goal of identifying better biomarkers and more effective treatment options for these diseases.

Her work has provided significant contributions to the current understanding of the two most common forms of lymphoid malignancies- follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL), by identifying multiple lymphoma driving genetic lesions in these cancers and demonstrating the role these genes play in both normal germinal center (GC) biology and the malignant transformation process.

Dr. Pasqualucci has authored more than 100 original publications and book chapters on the molecular pathogenesis of B cell lymphomas. She serves on numerous national and international advisory committees including the National Cancer Institute, the European Research Council, the Lymphoma Research Foundation, the Leukemia and Lymphoma Society, the American Society of Hematology, and the AACR among others. She is a Scientific Editor of Blood Cancer Discovery and a member of the Advisory Editorial Board for the Journal of Experimental Medicine.

# Multiple Myeloma and Lymphoma Research Symposium

## SPEAKER BIOGRAPHIES

INVITED SPEAKER

### Kieron M Dunleavy, MD

Professor of Oncology and Medicine  
Georgetown University  
Director, Hematological Malignancies  
Lombardi Comprehensive Cancer Center and Medstar Health



Dr. Dunleavy is a Professor of Medicine and Director of Hematology at Georgetown University in Washington DC. His work is focused on the biology and treatment of lymphoid diseases. He is particularly interested in aggressive B-cell lymphoma and virally-associated lymphomas and has worked on developing novel approaches for subtypes of diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). His interest extends to developing novel strategies within molecular subtypes of DLBCL and has been involved in work demonstrating that BTK inhibition is preferentially beneficial in the activated B-cell (ABC) subtype over the germinal center B-cell (GCB) subtype of DLBCL. This led his research team to test ibrutinib-based therapy in primary central nervous system lymphoma (PCNSL), which is currently ongoing in a clinical trial. His clinical drug development has spanned over Phase I, II and III clinical trials, principally in aggressive lymphoma. His other areas of focus include the biology and treatment of CNS lymphomas, Burkitt lymphoma and virally-driven lymphomas.

In addition, he is also the Chair of the Eastern Cooperative Oncology Group (ECOG) for a study focused on novel therapy in primary mediastinal B-cell lymphoma. He is also the co-chair of a Blood and Marrow Transplant Clinical Trials Network Protocol (AMC-109) evaluating novel cellular therapy in HIV-associated lymphoma.

INVITED SPEAKER

### Jing Yang, PhD

Associate Professor of Oncology  
Houston Methodist Cancer Center, Houston Methodist Research Institute



Jing Yang obtained her PhD from Xiangya Medical College in China. She then went on to complete her post-doctoral training at the University of Arkansas and MD Anderson Cancer Center. She is currently an Associate Professor of Oncology in the Houston Methodist Cancer Center.

Her current research goal is to improve the survival of patients with multiple myeloma through translating the bench work into new therapeutic approaches/strategies. Her research studies focuses on the underlying pathogenesis of myeloma and myeloma-associated bone disease, and the mechanisms of the resistance to chemotherapeutic or immunotherapeutic agents.

Her research focus extends to areas of obesity and cancer, tumor metabolism, tumor microenvironment (e.g., bone marrow adipocytes, bone cells, immune cells), and tumor bone metastasis and bone destruction. Her research findings provide novel rational strategies and tools for prognosis, prevention, or treatment of myeloma. The goal of her research is to elucidate the mechanisms of how myeloma cells escape the proteasome inhibitor-based therapy and the antibody-based immunotherapies, which are a standard-of care in myeloma patients.

## Samir Parekh, MD

Professor of Medicine and Oncological Sciences  
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai




Dr. Parekh completed his clinical training in Hematology and Oncology and postdoctoral training in Dr. Ari Melnick's lab at the Albert Einstein College of Medicine. He is the Director of Myeloma Translational Research and a Professor in Hematology-Oncology and Oncological Sciences at the Icahn School of Medicine at Mount Sinai. Dr. Parekh's research focuses on the pathogenesis of hematological malignancies and the development of individualized, precision-medicine therapies for these malignancies. His lab uses an integrated systems biology approach to study genome-wide methylation, gene expression, and DNA sequence variation to understand pathogenesis, develop biomarkers and guide personalized therapy in B cell malignancies, particularly Multiple Myeloma and Non-Hodgkin's lymphoma.

INVITED SPEAKER

## David R Fooksman, PhD

Associate Professor of Pathology, Microbiology and  
Immunology  
Albert Einstein College of Medicine



David Fooksman obtained his PhD at Johns Hopkins University under the mentorship of Dr. Michael Edidin, studying how the surface organization MHC Class I molecules regulates T cell receptor signaling using high-resolution imaging techniques. During his postdoctoral training at NYU School of Medicine with Dr. Michael Dustin and in collaboration with Michel Nussenzweig at Rockefeller University, David worked on B cell selection and differentiation in the context of the germinal centers and how plasma cell migration is regulated. There he learned how to conduct intra-vital imaging, which he uses currently to study basic physiology and function of normal and malignant plasma cells such as myeloma. The Fooksman is interested in survival and function of these cells and how the cell-cell communication regulates these processes in the bone marrow. The work in the lab has focused on how key molecules like CD138 and how inflammation regulate the dynamics of these cells.

INVITED SPEAKER

## ORGANIZERS

### Institute for Multiple Myeloma and Lymphoma Research



**Benjamin Tycko, MD PhD**

Member, HMH-CDI  
Professor of Medical Sciences

HMSOM  
Professor of Oncology  
Georgetown University &  
Lombardi Comprehensive Cancer  
Center



**Rena Feinman, PhD**

Associate Member, HMH-CDI  
Member, John Theurer Cancer  
Center

Associate Professor, Medical  
Sciences, HMH SOM  
Adjunct Associate Professor,  
Department of Oncology,  
Georgetown University Medical  
Center



**David Siegel, MD**

Chief, Division of Multiple  
Myeloma, John Theurer  
Cancer Center

Founding Director of IMML  
Professor, Department of  
Medical Sciences, Hackensack  
Meridian School of Medicine  
Professor, Department of  
Oncology, Georgetown  
University Medical Center



**David Perlin, PhD**

Chief Scientific Officer and  
Executive Vice President,  
Center for Discovery and  
Innovation

Professor of Biomedical Sciences  
Georgetown University

## NOTABLE SUPPORTERS



**Andre Goy, MD**

Physician in Chief Hackensack  
Meridian Health Oncology Care  
Transformation Services

Chairman & Chief Physician  
Officer, John Theurer Cancer  
Center at Hackensack  
University Medical Center

Lymphoma Division Chief, John  
Theurer Cancer Center



**Louis Weiner, MD**

Director, Georgetown Lombardi  
Comprehensive Cancer Center

Professor and Chair,  
Department of Oncology,  
Georgetown University Medical  
Center.

Director, MedStar Georgetown  
Cancer Institute



# Multiple Myeloma and Lymphoma Research Symposium



**Multiple Myeloma and  
Lymphoma  
Research Symposium**